JPMorgan Starts Amneal Pharmaceuticals (AMRX) at Neutral

JPMorgan initiates coverage on Amneal Pharmaceuticals (NYSE: AMRX) with a Neutral rating and a price target of $18.00.

Analyst Chris Schott sees LT growth potential for the company but comes out on the sidelines citing limitations to NT pipeline.

For an analyst ratings summary and ratings history on Amneal Pharmaceuticals click here. For more ratings news on Amneal Pharmaceuticals click here.

Shares of Amneal Pharmaceuticals closed at $16.81 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Perseus Mining Limited (PRU:AU) (PMNXF) to Neutral
• Tigress Financial Partners Starts Jersey Mike's Subs (JMKE) at Buy
• Abercrombie & Fitch (ANF) PT Raised to $175 at BTIG